Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.

Kastelan, Darko; Vlak, Tonko; Lozo, Petar; Gradiser, Marina; Mijic, Sime; Nikolic, Tatjana; Miskic, Blazenka; Car, Dolores; Tajsic, Gordana; Dusek, Tina; Jajic, Zrinka; Grubisic, Frane; Poljicanin, Tamara; Bakula, Miro; Dzubur, Fedja; Strizak-Ujevic, Matilda; Kadojic, Mira; Radman, Maja; Vugrinec, Maja; Kuster, Zeljka; Pekez, Marijeta; Radovic, Endi; Labar, Ljubica; Crncevic-Orlic, Zeljka; Korsic, Mirko.
Endocr Res; 35(4): 165-73, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20868288

OBJECTIVE:

The present study was designed to assess the effect of monthly ibandronate on health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates.

METHODS:

HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires.

RESULTS:

The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates.

CONCLUSION:

The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
Selo DaSilva